Pharmaceutical News

RSS

NIAID has awarded 10 grants and 2 contracts totaling approximately $27 million to fund development of new therapeutics and vaccines against bioterrorism

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded 10 grants and 2 contracts totaling approximately $27 million to fund development of new therapeutics and vaccines against some of the most deadly agents of bioterrorism including anthrax, botulinum toxin, Ebola virus, pneumonic plague, smallpox and tularemia.

11 May 2005

Canada may ban bulk exports of drugs to the United States

In a move to forestall a potential drug shortage in Canada, Canadian Health Minister Ujjal Dosanjh, is contemplating imposing a ban on bulk exports of drugs to the United States.

10 May 2005

Pharmacies in supermarkets: Where's the public benefit?

Protecting public health is more important than Woolworths' profits and should be the primary consideration in any government decision over whether to allow pharmacies in supermarkets, Pharmaceutical Society of Australia Vice-President Frank Payne said yesterday.

10 May 2005

Benitec announces clinical candidate for the treatment of Hepatitis C

Benitec Ltd. announced today that it has identified a highly promising clinical candidate for its RNA interference (RNAi)-based therapeutic against the hepatitis C virus (HCV).

10 May 2005

Cytogen Corporation and Dowpharma collaborate to create a targeted oncology product designed to treat prostate and other cancers

Under the agreement, Dowpharma's proprietary MeO-DOTA bifunctional chelant technology will be used to radiolabel Cytogen's prostate-specific membrane antigen (PSMA) antibody with a therapeutic radionuclide. PSMA is a protein highly expressed on the surface of prostate cancer cells and the neovasculature of many solid tumors.

10 May 2005

Fragile US vaccine system needs improvement

A comprehensive system of vaccine development in the U.S. resulted in a reduction of 87 to more than 99 percent in illness from ten vaccine-preventable diseases during the twentieth century. These dramatic successes should not be taken for granted, however, as the vaccine system now faces numerous challenges in manufacturing and development, according to a review article in the May/June issue of Health Affairs.

10 May 2005

Expert analyzes why manufacturers have gradually abandoned vaccines

Recent shortages of vaccines, most recently the flu vaccine during the past winter, are not short-term glitches--they reflect long-term problems in the vaccine industry. A variety of social, legal and economic forces have caused pharmaceutical companies to withdraw their commitment to vaccines, according to pediatrician and vaccine expert Paul A. Offit, M.D., chief of Infectious Diseases at The Children's Hospital of Philadelphia.

10 May 2005

Parkinson's drug Mirapex accused of causing gambling addiction

A drug prescribed to millions of patients in the U.S. as a treatment for Parkinson's disease and other conditions, has allegedly turned some patients into gambling addicts.

9 May 2005

New treatment improves visual acuity score of patients with retinitis pigmentosa

Neurotech SA announced positive results from an open-label Phase I clinical trial (03-EI-0234) of its lead product, NT-501. NT-501 uses Neurotech’s patented Encapsulated Cell Technology (ECT) as a device to deliver ciliary neurotrophic factor (CNTF) to eyes of visually impaired patients with retinitis pigmentosa (RP). Neurotech is a biotechnology company specializing in the development of novel therapeutics to treat diseases of the eye. The company is headquartered in Paris.

8 May 2005

New cervical cancer drug could be a bestseller

New data released yesterday says that a new vaccine that promises to protect against cervical cancer could offer wider resistance to the disease than previously thought.

5 May 2005

New Zealand Ministry of Health to consider Vaxigrip vaccine trial results

Pharmac and the New Zealand Ministry of Health are aware that Sanofi-Pasteur has been running a clinical trial to demonstrate the efficacy of their influenza vaccine, Vaxigrip.

4 May 2005

pSivida's BrachySil takes first step in regulatory programme leading to product approval

pSivida Limited has announced that current data from its lead cancer product BrachySil will be presented at this year's European Society for Therapeutic and Radiation Oncology Conference in Budapest on May 5, 2005. The conference is an opportunity to share and validate the Company's promising findings with an international scientific, clinical and industrial audience.

3 May 2005

Boostrix receives FDA approval as treatment for pertussis

GlaxoSmithKline today announced that its booster vaccine, Boostrix received approval from the United States (U.S.) Food and Drug Administration (FDA).

3 May 2005

Promising results from study of Pirfenidone in idiopathic pulmonary fibrosis (IPF) patients

InterMune today announced that the American Journal of Respiratory and Critical Care Medicine (AJRCCM) published results from a double-blind, randomized, placebo-controlled Phase II trial evaluating pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF).

2 May 2005

Myogen's Ambrisentan granted orphan drug designation by Europeans

Myogen today announced that the Commission of the European Communities, with a favorable opinion of the Committee for Orphan Medicinal Products of the European Medicines Agency (EMEA), has granted orphan drug designation to ambrisentan for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension.

2 May 2005

FDA to change regulations regarding side-effect information in drug ads

The Food and Drug Administration is about to make it easier for you to understand both the benefits and risks of a prescription medication, it was revealed at the Second Annual Medical Liaison Seminar sponsored here by Scientific Advantage LLC.

2 May 2005

GlaxoSmithKline to acquire Corixa Corporation

GlaxoSmithKline has announced the execution of a definitive agreement pursuant to which GSK will acquire Corixa Corporation, a developer of innovative products that regulate immunity, based in Seattle, WA (USA).

2 May 2005

Judge calls GlaxoSmithKline 'high-handed' over legal action from Biota

A Supreme Court judge in Melbourne, Australia has described as "high-handed" the delay by global pharmaceutical firm GlaxoSmithKline (GSK) in filing a defence against legal action from Biota Holdings last Friday.

1 May 2005

FDA gives go-ahead for new diabetes treatment

Sufferers from adult-onset diabetes, the most common form of the disease, will soon be able to access a new injectable diabetes treatment which when used with oral drugs, should be more effective in controlling their blood sugar.

1 May 2005

Generex begins testing new vaccine for breast cancer patients

Generex Biotechnology Corporation announced today that the first patients had received a novel therapeutic vaccine developed by its wholly owned subsidiary, Antigen Express as part of the Company's Phase I Trial. The Trial will include between 16 and 24 patients.

28 Apr 2005